Regulation of the FXR/TLR4 Axis and Ferroptosis by hsa_circ_0001944 in Nickel Oxide Nanoparticle-Induced Liver Fibrosis

1. Study Background and Research Question

Nickel oxide nanoparticles (NiONPs) are increasingly prevalent in industrial applications, raising concerns about their potential hepatic toxicity upon environmental or occupational exposure. Prior reports have established that NiONPs can drive liver fibrosis through the activation of hepatic stellate cells (HSCs) and subsequent collagen deposition. However, the detailed molecular mechanisms—especially the interplay between non-coding RNAs, nuclear receptor signaling, innate immune pathways, and regulated cell death—remain incompletely understood. The reference study (Zhou et al., 2025) specifically addresses how hsa_circ_0001944, a circular RNA, modulates the farnesoid X receptor (FXR)/Toll-like receptor 4 (TLR4) pathway and ferroptosis to counteract NiONP-induced collagen formation in HSCs.

2. Key Innovation from the Reference Study

The key innovation of this work is the identification of a previously uncharacterized regulatory axis involving hsa_circ_0001944, FXR, TLR4, and ferroptosis in the context of NiONP-induced liver fibrosis. Through a combination of in vitro and in vivo models, the authors demonstrate that overexpression of hsa_circ_0001944 upregulates FXR, downregulates TLR4, promotes ferroptosis, and ultimately alleviates collagen deposition in human LX-2 hepatic stellate cells. This finding uncovers a mechanistic bridge between non-coding RNA regulation, nuclear receptor signaling, innate immunity, and iron-dependent cell death—a cross-talk that had not been directly linked in the context of nanoparticle-induced fibrogenesis prior to this study (Zhou et al., 2025).

3. Methods and Experimental Design Insights

The research integrated both rat models of liver fibrosis and an in vitro LX-2 cell collagen deposition system to dissect the underlying mechanisms. Key methodological features include:

• Exposure of rats and LX-2 cells to NiONPs to induce fibrosis and collagen formation.
• Assessment of FXR and TLR4 expression by qPCR and immunoblotting, and characterization of ferroptosis markers such as glutathione peroxidase 4 (GPX4), glutathione (GSH), and malondialdehyde (MDA).
• Use of pharmacological modulators: GW4064 (FXR agonist), TAK-242 (selective TLR4 inhibitor), and Erastin (ferroptosis inducer) to interrogate pathway relationships.
• Bioinformatics analyses to predict potential regulation of FXR by hsa_circ_0001944, validated by overexpression experiments in LX-2 cells.
• Evaluation of collagen deposition via measurement of type I collagen (COL1A1) and extracellular matrix markers.

Protocol Parameters

• NiONP exposure: Dose and duration tailored to induce fibrosis in rats and LX-2 cells; see reference study for detailed concentrations.
• TAK-242 treatment: Applied as a TLR4 pathway inhibitor to LX-2 cells; concentrations aligned with prior literature (typically in the nanomolar range for in vitro work; refer to product information for solubility and storage guidance).
• GW4064 and Erastin: Used to activate FXR and induce ferroptosis, respectively, enabling pathway dissection.
• hsa_circ_0001944 overexpression: Achieved by transfection of LX-2 cells with expression constructs validated by qPCR.

4. Core Findings and Why They Matter

The study uncovered several mechanistically significant findings:

• NiONP exposure decreased FXR and increased TLR4 expression in both rat livers and LX-2 cells, fostering a pro-fibrotic, pro-inflammatory milieu.
• Ferroptosis features (e.g., lipid peroxidation, decreased GPX4/GSH, elevated MDA) were altered in NiONP-treated models, implicating iron-dependent cell death in fibrosis progression.
• TAK-242 (Resatorvid) treatment alleviated collagen deposition by inhibiting TLR4 and promoting ferroptosis in LX-2 cells, supporting a causative role for TLR4 signaling in fibrosis and a potential antifibrotic effect of controlled ferroptosis induction.
• Activation of FXR (with GW4064) suppressed TLR4, increased ferroptosis markers, and mitigated collagen deposition, highlighting a negative regulatory relationship between FXR and TLR4 in this context.
• Bioinformatics and experimental validation established that hsa_circ_0001944 upregulates FXR and suppresses TLR4, thereby enhancing ferroptosis and reducing fibrosis.
• Overexpression of hsa_circ_0001944 reversed the effects of NiONP exposure on FXR/TLR4/ferroptosis/collagen axis, demonstrating a non-coding RNA-driven checkpoint in the antifibrotic response.

These results position the FXR/TLR4/ferroptosis axis as a pivotal regulatory hub in nanoparticle-induced fibrogenesis, and suggest that modulation of TLR4 signaling or ferroptosis may be viable strategies for antifibrotic intervention (Zhou et al., 2025).

5. Comparison with Existing Internal Articles

The mechanistic insights from Zhou et al. extend and complement internal reviews such as "Rewiring Inflammation: TAK-242 and the Next Frontier in TLR4 Targeting", which discusses TAK-242’s role in TLR4 signaling pathway modulation across fibrosis and neuroinflammation models. While the internal article focuses on strategic deployment of TAK-242 (Resatorvid) for inhibition of LPS-induced inflammatory cytokine production and broader immune modulation, the reference paper provides specific evidence for the antifibrotic and ferroptosis-promoting effects of TLR4 inhibition in the context of nanoparticle toxicity.

Additionally, "TAK-242: Selective TLR4 Inhibitor for Advanced Neuroinflammation Research" provides protocol-level guidance for employing small-molecule TLR4 inhibitors to suppress inflammatory signal pathways. The current study offers complementary evidence for the utility of TAK-242 in fibrosis models, underscoring the translational potential of TLR4 blockade beyond neuroinflammation.

6. Limitations and Transferability

Several limitations should be noted:

• Cell line specificity: The in vitro findings are based on LX-2 cells, a human hepatic stellate cell line, which may not fully recapitulate the complexity of in vivo fibrosis.
• Translational scope: While the rat model supports in vivo relevance, direct extrapolation to human disease or other organ systems requires further investigation.
• Pathway specificity: The study focuses on the FXR/TLR4/ferroptosis axis; other parallel or intersecting pathways may also contribute to NiONP-induced fibrosis but were not explored.
• Temporal and dosage parameters: Detailed optimization of exposure times and concentrations for each intervention is necessary for reproducibility in other models.

7. Research Support Resources

For researchers aiming to replicate or extend these findings, a selective TLR4 inhibitor such as TAK-242 (Resatorvid) (SKU A3850) is available from APExBIO and is widely used for TLR4 signaling pathway inhibition in fibrotic, inflammatory, and neuroinflammation research. The compound is effective in suppressing LPS-induced inflammatory cytokine production and has demonstrated utility in both in vitro and preclinical animal models. When designing experiments, refer to product-specific solubility and storage instructions, such as use of DMSO stocks and -20°C storage for stability.